Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)

Ki vehet részt

• Patient diagnosed with chronic (ITP with > 1 year duration) primary ITP living in the USA or the UK:; On ITP pharmacologic treatment, , including on-demand treatment strategy, regardless of last platelet count (below or above 100 x 10\^9 counts/L); Patients with their most recent platelet count >50 x 109 counts/L) and without any ITP-specific treatment for 1 year or less
• Adult patient who are 18 years or older at index date
• Patient who has received at least one initial first line ITP therapy (CS/ IVIg/ANTI d) with initial response as of index date and indicated by one of the following:; Platelet count ≥ 50 x 10\^9 counts /L; OR; Platelet count ≥ 30 x 10\^9 counts /L with at least a two-fold increase from baseline within 1 month since start of treatment, as per ASH 2019 guidelines; OR; A medical record of initial response as determined by clinical judgement, considering documented platelet count along with overall patient condition and relevant medical factors
• Patients whose medical history related to the study objectives are available from the site covering 12 months prior to index date
• Patient provided informed consent to participate in the study

Ki nem vehet részt

• Patients with vaccination in 28 days before index date
• Patients treated with rilzabrutinib on or before index date
• Patients who participated in an interventional clinical trial for any investigational drug in the 180 days prior to index date
• Patients with recent or active infection recorded 14 days or less before index date; patients with uncontrolled chronic infections or who were recently diagnosed with a chronic infection (≤14 days of index date)
• Patients with their most recent platelet count >50 x 10\^9 counts/L and without any ITP-specific treatment for more than 1 year
• Secondary ITP